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osting by EAbstract Down syndrome is known to be an independent risk factor for mortality after surgical
repair of congenital heart anomalies. It is also associated with neurodegenerative disease and accel-
erated aging. The mechanism of the latter features has been attributed to abnormal handling of oxy-
gen-free radicals as well as mitochondrial dysfunction. These properties also place the child with
Down syndrome at a risk of an exaggerated myocardial ischemia/reperfusion injury.
A 6 month old child with Down syndrome is reported who suffered from obvious clinical ische-
mia/reperfusion injury following an uncomplicated repair of complete AV canal. Both intraopera-
tive as well as postoperative echocardiography documented a satisfactory technical repair. After
resting the heart on ECMO the child’s myocardial function returned to normal.
The mechanisms by which patients with Down syndrome are at risk of ischemia/reperfusion
injury are reviewed. Future studies should focus on speciﬁc approaches for myocardial protection
in the child with Down syndrome undergoing cardiac surgery.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Contents
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chromosome 21 is associated with a high incidence of congen-
ital heart defects, mental retardation, early onset Alzheimer’s
disease and an accelerated aging process among other deleteri-
ous phenotypes (Tiano et al., 2008; Pallardo´ et al., 2006). An
imbalance in redox metabolism resulting in oxidative stress
and tissue injury has been shown to be the basic defect under-
lying this disorder (Tiano et al., 2008; Pallardo´ et al., 2006).
Gene-dose effect leads to elevated levels of superoxide dismu-
tase-1(SOD-1) which results in an excess of reactive oxygen
species (ROS) formation and consequent cell injury (Zigman
and Lott, 2007). In recent years focus has shifted to abnormal-
ities in mitochondrial function as an additional mechanism of
cell injury (Conti et al., 2007; Prince et al., 1994; Arbuzova
et al., 2002) in DS. Reperfusion following a period of ischemia
is associated with generation of superoxide radicals and alter-
ations in mitochondrial membrane (Yellon and Hausenloy,
2007). Although both redox metabolism and mitochondrial
function are now known to be abnormal in DS, the issue of
myocardial reperfusion injury either potential or real has not
raised before. We report a case of myocardial reperfusion in-
jury following open heart surgery in an infant with DS and dis-
cuss the possible mechanisms of the same.
1. Clinical summary
UL, a nearly 6 month old girl was diagnosed with Down syn-
drome and complete atrioventricular canal at birth. Although
surgical intervention for her congenital heart disease was ini-
tially planned at 3 months, it was delayed because of serious
social reasons. She was medically managed with decongestive
therapy for heart failure and weighed 5.3 kg at the time of
operation. CXR showed cardiomegaly with pulmonary pleth-
ora. Electrocardiogram revealed prominent biventricular
forces. Echocardiogram (ECHO) showed a complete atrioven-
tricular (AV) canal (Rastelli type A) with a large ventricular
septal defect (VSD) and a large atrial component. Both the
AV valves were competent. There was a bridging band of tis-
sue between the superior and inferior common leaﬂets natu-
rally dividing the AV valve into right and left components.
In addition there was a moderate-sized ostium secundum
defect.
Surgical repair of her congenital defect was undertaken
under cardiopulmonary bypass. A standard midline sternot-
omy approach was used. Cardiopulmonary bypass (CPB)
was instituted using aortic and bicaval cannulation. The pat-
ent ductus arteriosus was ligated soon after going on bypass.
The patient was cooled to 28 C. Aorta was cross clamped
and the heart arrested using antegrade cardioplegia (we
use oxygenated St. Thomas crystalloid cardioplegia solution
for myocardial arrest at our institution). The heart arrested
satisfactorily with complete disappearance of electrical activ-
ity. The caval tourniquets were tightened and right atrium
(RA) was opened by an oblique incision running parallel
to the atrioventricular groove. The ECHO diagnosis of
CAVC type A was conﬁrmed. The band of tissue betweenthe bridging leaﬂets was used as a guide to demarcate the
left from the right AV valve. Modiﬁed single patch tech-
nique was used for repair of the AV canal defect. The cleft
in the left AV valve was repaired and both the atrial septal
defects were closed using a single pericardial patch. The cor-
onary sinus was placed on the left side of the patch. Half-
dose cardioplegia was used intermittently at intervals of
20 min or earlier if there were signs of electrical activity.
Rewarming was initiated towards the end of procedure.
The heart was thoroughly deaired and the cross clamp was
released with the cardioplegia site bleeding freely. The total
cross clamp time was 39 min with two additional half doses
of cardioplegia following the ﬁrst full dose. At this point we
noted that the myocardial perfusion was poor and the heart
did not appear pink as it would normally do following re-
lease of cross clamp. It was hoped that this was a transient
phenomenon and would rapidly improve. Epicardial pacing
was used for variable heart block with intermittent periods
of sinus rhythm. Upon complete rewarming, the child was
weaned from cardiopulmonary bypass using 7.5 mg/kg/min
of dopamine with systolic blood pressure in the 50 s and left
atrial pressure between 12 and 15 mmHg. The total duration
of cardiopulmonary bypass was 70 min. However, the myo-
cardial perfusion continued to look poor with ST elevation
in all the leads. There was some improvement in hemody-
namics with return of sinus rhythm and escalation of dopa-
mine support but with no difference in the color of the
heart. About 30 min following weaning from CPB, the
hemodynamics deteriorated and the child had to be placed
back on CPB. A decision was made to rest the heart on
Extracorporeal membrane oxygenation (ECMO) instead of
attempting another wean with high pressors. A left atrial
vent was placed to decompress the left heart. The perfusion
of the heart remained concerningly poor through all this.
There was rapid return of pulsatility on ECMO. ECHO
conﬁrmed an adequate repair with mild to moderate left AV
valve regurgitation. At the time of removal of left atrial vent
24 h later, we noted a signiﬁcant change in the color of the
heart. The heart appeared pink and well perfused for the ﬁrst
time following the operation and there was also a notable
improvement in contractility. The patient could be easily
weaned off ECMO within the next 24 h. She had an unremark-
able post operative course following ECMO decannulation
and was discharged home.
2. Discussion
Myocardial reperfusion injury is the injury caused to the myo-
cardium by restoration of blood ﬂow after an ischemic episode.
This results in death or damage to the cardiac myocytes that
were viable immediately before myocardial reperfusion. Myo-
cardial reperfusion injury was ﬁrst postulated by Jennings et
al. in 1960. The injury that occurs to the myocardium on re-
lease of aortic cross clamp following cardioplegic arrest of
the heart is a form of myocardial reperfusion injury. The reper-
fusion injury can manifest as four types of cardiac dysfunction
Figure 1 showing the mediators of myocardial reperfusion injury and the potential steps that could be affected in Down’s syndrome.
N = neutrophil. E = vascular endothelium. PTP = permeability transition pore. ROS = reactive oxygen species. SR = sarcoplasmic
reticulum.
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mechanical dysfunction that persists after reperfusion despite
the absence of irreversible damage and despite the restoration
of normal or near normal coronary ﬂow. This is a relatively
mild sublethal injury and results in global derangement of
the mechanical properties of the heart. This heart usually
recovers from this sort of injury within a few days to weeks.
The second type of injury is the ‘no reﬂow’ phenomenon which
refers to the inability to reperfuse a previously ischemic region
due to impedence of microvascular blood ﬂow following resto-
ration of blood ﬂow. Reperfusion arrhythmias are the third
type of injury and are often amenable to treatment. Lethal
reperfusion injury causes death of the cardiomyocytes and is
fatal.
Mediators of reperfusion injury (Fig. 1) have been well de-
scribed (Yellon and Hausenloy, 2007).
1. Oxygen paradox. The reperfusion of ischemic myocardium
generates harmful oxidative radicals termed reactive oxy-
gen species (ROS) which can itself mediate myocardial
injury. The ROS such as O2
, H2O2 and OH
 also reduces
the bioavailability of the intracellular signaling molecule
like NO which has cardioprotective affects.
2. Calcium paradox. Reperfusion results in an abrupt increase
in intracellular calcium secondary to sarcolemmal mem-
brane damage and oxidative stress induced dysfunction of
the sarcoplasmic reticulum. This resulting calcium overload
induces cardiomyocyte death by causing hypercontracture
of myocardial cells and opening of mitochondrial perme-
ability transition protein (PTP).
3. PH paradox. The correction of pH following washout of
lactic acid and activation of membrane channels contrib-
utes to reperfusion injury by activation of PTP.4. Inﬂammation. Neutrophils are drawn into the injured area
by the chemoattractants released by the myocardium fol-
lowing reperfusion. This is facilitated by the cell adhesion
molecules. The neutrophils inﬂict damage by causing vas-
cular plugging and release of degradative enzymes and
ROS.
5. Mitochondrial PTP. The mitochondrial PTP is a nonse-
lective channel of the inner mitochondrial membrane.
Opening of the channel collapses the mitochondrial
membrane potential and uncouples oxidative phosphory-
lation resulting in ATP depletion and death. The chan-
nel is closed during ischemia and opens with reperfusion
in response to mitochondrial calcium overload, oxidative
stress, restoration of physiological pH and ATP
depletion.
2.1. Down’s syndrome
Studies suggest that multiple chromosome 21 genes affect pro-
tein synthesis, mitochondrial function and reactive oxygen spe-
cies production, one carbon metabolism and cell adhesion
(Conti et al., 2007). Mitochondrial function and ROS path-
ways have been targets of numerous studies on neurodegener-
ation in DS (Tiano et al., 2008; Pallardo´ et al., 2006; Conti
et al., 2007; Prince et al., 1994; Arbuzova et al., 2002; Busciglio
et al., 2002; Shukkur et al., 2006).
SOD-1 is a key enzyme involved in the metabolism of reactive
oxygen species (ROS). Normally it protects against free radical in-
jury by converting superoxide anion (O2
) into H2O2 which is
further broken down by glutathione peroxidase to H2O. SOD-1
level is markedly raised in DS as the gene for SOD-1 is located
on chromosome 21. The increased level of SOD-1, a molecular
16 S. Kumar, R. Jonasmarker of DS can lead to the accumulation of ROS like OH
which can damage DNA, RNA, proteins and lipids. This oxida-
tive stress has been implicated in the neuronal injury leading to
mental retardation and early onset of Alzheimer’s disease in DS
(Brugge et al., 1992; Sinha, 2005). Oxidative stress also causes
accelerated aging process (Pallardo´ et al., 2006).
On studying the gene expression proﬁles of the hearts of hu-
man fetuses with Down’s syndrome Conti et al. found that
chromosome 21 gene expression was globally up regulated
1.5-fold. Interestingly, not all genes were equally upregulated
and genes located on other chromosomes were also signiﬁ-
cantly dysregulated (Conti et al., 2007). Further analyses re-
vealed down regulation of genes encoding mitochondrial
enzymes and up regulation of genes encoding extra cellular
matrix proteins. Reduction of mitochondrial enzyme activity
has been reported in platelets from DS patients (Prince et al.,
1994) as well as in astrocytes and primary cultures of ﬁbro-
blasts (Arbuzova et al., 2002; Busciglio et al., 2002). Shukkur
et al. elegantly demonstrated the contribution of mitochon-
drial dysfunction to neurodegeneration in a mouse mode of
DS (Shukkur et al., 2006). Mitochondrial dysfunction has thus
come to be increasingly recognized as an additional contribut-
ing factor to the pathology of DS.
Neutrophil chemotaxis and phagocytic activity have been
proven to be adversely affected in DS (Zaldivar-Chiapa
et al., 2005).
Thus it is easy to see how DS patients may respond differ-
ently to the reperfusion injury (Fig. 1) as ROS formation, mito-
chondria and leukocyte play a key role in it although we do not
know how theymay combine to produce a different response. In
our case, we used the same standard cardioplegia at the same
intervals as in any other patient. The heart responded well to
the cardioplegic arrest and there were no signs of electric activity
on ECG during the period of aortic cross clamp. Deairing of the
heart was thorough before release of cross clamp and there were
no signs of coronary air embolism. Mechanical dysfunction
accompanied the pale color of the heart and both improved over
a period of 24 h. The senior author of this paper has encoun-
tered a similar case of reperfusion injury in a Down’s syndrome
with AV canal defect. In that case too, the patient recovered
after being placed on ECMO.
DS patients form a signiﬁcant proportion of those requiring
repair of congenital heart lesions. The question of vulnerability
of these hearts to reperfusion injury has not been raised before
probably because most of the cardioplegia in use afford good
myocardial protection from anoxic damage in these hearts
too. It is also probable that cases of reperfusion injury in the past
have either not been reported or they have gone unrecognized.
Moreover individuals with DS are affected to a variable extent,
the mechanism of which is yet not understood (Wiseman et al.,
2009). Sinha has demonstrated the differential expression of
the antioxidant genes in DS depending on age and sex (Sinha,
2005). Further studies are required to understand not only the
myocardial reperfusion injury in DS but also the inﬂammatory
response to CPB.3. Conclusion
The underlying mechanisms operative in DS pathology may
make them vulnerable to myocardial reperfusion injury follow-
ing open heart surgery as it did in our case. Awareness of this is
important to recognize and deal with this form of reperfusion
injury. More studies and research are required in this direction
to understand this.
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